Monographie - Fluorouracil

Pēdējā atjaunošana :
19/11/2024

Fluorouracil

Ķīmiskā uzbūve

Oriģinālais nosaukums

Tirdzniecības nosaukumi ir apzīmējoši un palīgvielas var atšķirties dažādām valstīm un laboratorijām

Acoflut	Meksika
Adrucil	Amerikas Savienotās Valstis
Eurofluor	Vācija
Fivocil	Indija
Fivoflu	Indija, Meksika
Fluorouracil	Amerikas Savienotās Valstis, Austrija, Beļģija, Brazīlija, Dānija, Dienvidāfrikas Republika, Dienvidslāvija, Grieķija, Holande, Itālija, Kanāda, Lielbritānija, Norvēģija, Polija, Portugāle, Somija, Spānija, Šveice, Turcija, Ungārija
Fluorouracile	Francija
Flurablastin	Dānija, Norvēģija, Somija, Zviedrija
Fluracedyl	Beļģija, Holande, Luksemburga, Malaizija
Fluroblastin	Dienvidāfrikas Republika
Fluroblastine	Beļģija
Flurox	Meksika
Neofluor	Vācija
Neoflur	Ēģipte
Oncofu	Argentīna
Ribofluor	Vācija
Triosules	Argentīna

Literatūras saraksts : Fluorouracil

	tips	publicēšana
3	Žurnāls	Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
5	Žurnāls	Stiles ML, Allen LV Jr, Prince SJ. Stability of deferoxamine mesylate, floxuridine, fluorouracil, hydromorphone hydrochloride, lorazepam, and midazolam hydrochloride in polypropylene infusion-pump syringes. Am J Health-Syst Pharm 1996 ; 53: 1583-1588.
33	Žurnāls	Baud-Camus F, Crauste-Manciet S, Klein E, Richard L, Brossard D. Stability of fluorouracil in polypropylene syringes and ethylene vinyl acetate infusion-pump reservoirs. Am J Health-Syst Pharm 1996 ; 53: 1457-1458.
39	Žurnāls	Farhang-Asnafi S, Callaert S, Barre J, Tillement JP, Thebault A. Influence of intravenous admixtures on the stability of the new solution of 5-fluorouracil. J Pharm Clin 1997 ; 16: 45-48.
40	Žurnāls	Dine T, Lebegue S, Benaji B, Gressier B, Segard V, Goudaliez F, Luyckx M, Brunet C, Mallevais ML, Kablan J, Cazin M, Cazin JC. Stability and compatibility studies of four cytostatic agents (fluorouracil, dacarbazine, cyclophosphamide and ifosfamide) with PVC infusion bags. Pharm Sci Communications 1994 ; 4: 97-101.
49	Žurnāls	Trissel LA, Martinez JF. Compatibility of granisetron hydrochloride with selected alkaline drugs. Am J Health-Syst Pharm 1995 ; 52: 208.
57	Žurnāls	Mayron D, Gennaro AR. Stability and compatibility of granisetron hydrochloride in IV solutions and oral liquids and during simulated Y-site injection with selected drugs. Am J Health-Syst Pharm 1996 ; 53: 294-304.
81	Žurnāls	Trissel LA, Martinez JF. Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 672-678.
84	Žurnāls	Trissel LA, Martinez JF. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 495-499.
85	Žurnāls	Trissel LA, Bready BB. Turbidimetric assessment of the compatibility of taxol with selected other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 1716-1719.
91	Žurnāls	Lober CA, Dollard PA. Visual compatibility of gallium nitrate with selected drugs during Y-site injection. Am J Hosp Pharm 1993 ; 50: 1208-1210.
99	Žurnāls	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
110	Žurnāls	Vincke BJ, Verstraeten AE, El Eini DID, Mc Carthy TM. Extended stability of 5-fluorouracil and methotrexate solutions in PVC containers. Int J Pharm 1989 ; 54: 181-189.
138	Žurnāls	Corbrion V, Crauste-Manciet S, Allain P, Brossard D. Precipitation of fluorouracil in elastomeric infusers with a polyisoprene reservoir and in polypropylene syringes with an elastomeric joint. Am J Health-Syst Pharm 1997 ; 54: 1845-1848.
142	Žurnāls	Rochard EB, Barthes DMC, Courtois PY. Stability of fluorouracil, cytarabine, or doxorubicin hydrochloride in ethylene vinylacetate portable infusion-pump reservoirs. Am J Hosp Pharm 1992 ; 49: 619-623.
153	Žurnāls	Wang DP, Chang LC, Lee DK. Stability of fluorouracil-metoclopramide hydrochloride admixture. Am J Health-Syst Pharm 1995 ; 52: 98-99.
155	Žurnāls	Trissel LA, Martinez JF, Xu QA. Incompatibility of fluorouracil with leucovorin calcium or levoleucovorin calcium. Am J Health-Syst Pharm 1995 ; 52: 710-715.
156	Žurnāls	Barberi-Hayob M, Merlin JL, Vigneron M, Conroy T. Addition of heparin in 5-fluorouracil solution for portal vein infusion has no influence on its stability under clinically relevant conditions. Anticancer Drugs 1995 ; 6: 163-164.
163	Žurnāls	Sewell GJ, Allsopp M, Collinson MP, Tyrrell C, Prentice AJ, Copplestone JA. Stability studies on admixtures of 5-fluorouracil with carboplatin and 5-fluorouracil with heparin for administration in continuous infusion regimens. J Clin Pharm Ther 1994 ; 19: 127-133.
169	Žurnāls	Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1993 ; 50: 2359-2363.
182	Žurnāls	Trissel LA, Gilbert DL, Martinez JF. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 56-60.
244	Žurnāls	Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913.
249	Žurnāls	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251	Žurnāls	Trissel LA, Gilbert DL, Martinez JF. Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
300	Žurnāls	Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301	Žurnāls	Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
307	Žurnāls	Trissel LA, Martinez JF. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1792-1799.
334	Žurnāls	Trissel LA, Tramonte SM, Grilley BJ. Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 988-992.
335	Žurnāls	Trissel LA, Bready BB, Kwan JW, Santiago NM. Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 402-406.
411	Žurnāls	Woloschuk DMM, Wermeling JR, Pruemer JM. Stability and compatibility of fluorouracil and mannitol during simulated Y-site administration. Am J Hosp Pharm 1991 ; 48: 2158-2160.
413	Žurnāls	Stewart CF, Fleming RA. Compatibility of cisplatin and fluorouracil in 0.9% sodium chloride injection. Am J Hosp Pharm 1990 ; 47: 1373-1377.
415	Žurnāls	Stiles ML, Allen LV, Tu YH. Stability of fluorouracil administered through four portable infusion pumps. Am J Hosp Pharm 1989 ; 46: 2036-2040.
431	Žurnāls	McRae MP, King JC. Compatibility of antineoplastic, antibiotic and corticosteroid drugs in intravenous admixtures. Am J Hosp Pharm 1975 ; 33: 1010-1013.
484	Žurnāls	Northcott M, Allsopp MA, Powell H, Sewell GJ. The stability of carboplatin, diamorphine, 5-fluorouracil and mitozantrone infusions in an ambulatory pump under storage and prolonged “in use” conditions. J Clin Pharm Ther 1991 ; 16: 123-129.
492	Žurnāls	Trissel LA, Parks NPT, Santiago NM. Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2186-2189.
513	Žurnāls	Xu QA, Trissel LA, Martinez JF. Stability and compatibility of fluorouracil with morphine sulfate and hydromorphone hydrochloride. Ann Pharmacotherapy 1996 ; 30: 756-761.
514	Žurnāls	Xu QA, Trissel LA, Martinez JF. Rapid loss of fentanyl citrate admixed with fluorouracil in polyvinyl chloride containers. Ann Pharmacotherapy 1997 ; 31: 297-302.
763	Žurnāls	Cohen MH, Jonhson-Early A, Hood MA, McKenzie M, Citron ML, Jaffe N, Krasnow SH. Drug precipitation within IV tubing : A potential hazard of chemotherapy administration. Cancer Treat Rep 1985 ; 69: 1325-1326.
840	Žurnāls	Biondi L, Nairn JG. Stability of 5-fluorouracil and flucytosine in parenteral solutions. Can J Hosp Pharm 1986 ; 39: 60-66.
842	Žurnāls	Pinguet F, Favre G, Canal P, Pujol A, Soula G. Stability of 5-fluorouracil to heat and light. J Pharm Clin 1990 ; 9: 155-158.
844	Žurnāls	Rochard E, Chapelle G, Bouquet S, Barthes D, Courtois PH. Stability of fluorouracil and cytarabine in ethylvinylacetate containers. J Pharm Clin 1989 ; 9: 31-35.
905	Žurnāls	Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017.
921	Žurnāls	Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292.
1026	Žurnāls	Mayron D, Gennaro AR. Stability and compatibility of topotecan hydrochloride with selected drugs. Am J Health-Syst Pharm 1999 ; 56: 875-881.
1040	Žurnāls	Quebbeman EJ, Hamid AAR, Hoffman NE, Ausman RK. Stability of fluorouracil in plastic containers used for continuous infusion at home. Am J Hosp Pharm 1984 ; 41: 1153-1156.
1228	Žurnāls	Allen LV, Stiles ML. Compatibility of various admixtures at Y-injection sites of intravenous administration sets. Part2. Am J Hosp Pharm 1981 ; 38: 380-381.
1325	Žurnāls	Hardin TC, Clibon U, Page CP, Cruz AB. Compatibility of 5-fluorouracil and total nutrition solutions. JPEN 1982 ; 6: 163-165.
1410	Žurnāls	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1415	Žurnāls	Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M. Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPEN 1999 ; 23: 67-74.
1423	Žurnāls	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1475	Žurnāls	Martel P, Petit I, Pinguet F, Poujol S, Astre C, Fabbro M. Long-term stability of 5-fluorouracil stored in PVC bags and in ambulatory pump reservoirs. J Pharm Biomed Anal 1996 ; 14: 395-399.
1501	Žurnāls	Beitz C, Bertsch T, Hannak D, Schrammel W, Einberger C, Wehling M. Compatibility of plastics with cytotoxic drug solutions - comparison of polyethylene with other container materials. Int J Pharm 1999 ; 185: 113-121.
1520	Laboratorija	Etude de stabilité des médicaments en Ecoflac® B Braun 2001
1625	Žurnāls	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1812	Žurnāls	Fuhrman LC, Godwin DA, Davis RA. Stability of 5-fluorouracil in an extemporaneously compounded ophtalmic solution. Int J Pharm Compound 2000 ; 4, 4: 320-323.
1817	Žurnāls	Roberts S, Sewell GJ. Stability and compatibility of 5-fluorouracil infusions in the Braun Easypump®. J Oncol Pharm Practice 2003 ; 9: 109-112.
1842	Žurnāls	Sadjack A, Wintersteiger R. Compatibility of morphin, baclofen, floxuridine and fluorouracil in an implantable infusion pump. Arzneimittel Forschung 1995 ; 45: 93-98.
1925	Žurnāls	Trissel LA , Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.
1953	Žurnāls	Trissel LA, Saenz CA, Ogundele AB, Ingram DS. Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
1982	Žurnāls	Trissel LA, Ogundele AB. Compatibility of anidulafungin with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2005 ; 62: 834-837.
1998	Žurnāls	Allwood MC. Fluorouracil precipitate. Am J Health-Syst Pharm 1998 55: 1315-1316.
2009	Žurnāls	Trissel LA, Zhang Y. Physical and chemical stability of palonosetron hydrochloride with fluorouracil and with gemcitabine hydrochloride during simulated Y-site administration. Int J Pharm Compound 2005 ; 2005, 9, 4: 320-322.
2130	Žurnāls	Lokiec F, Amirault P, Bonnans H, Gauzan MF, Sauvage N, Santoni J. Stabilité du mélange 5-fluoro-uracil-acide fonique : influence des concentrations, du contenant et de la forme de l’acide folinique. Bull Cancer 1999 ; 86, 11: 946-954.
2181	Žurnāls	Milano G, Renée N. Etude de compatibilité physicochimique 5- fluoro-uracile (nouvelle préparation française) - acide folinique. Bull Cancer 1995 ; 82: 189-195.
2262	Žurnāls	Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D. Compatibility of doripenem with other drugs during simulated Y-site administratioN Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
2323	Žurnāls	Galanti L, Lebitasy M.P, Hecq J.D, Cadrobbi J, Vanbeckbergen D, Jamart J. Long-Term Stability of 5-Fluorouracil in 0.9% Sodium Chloride after Freezing, Microwave Thawing, and Refrigeration Can J Hosp Pharm 2009 ; 62, 1
3369	Laboratorija	Levofolinate de sodium Medac - Résumé des caractéristiques du produits MEDAC France 2011
3474	Laboratorija	Fluorouracil - Summary of Product Characteristics Accord Healthcare Limited 2009
3531	Laboratorija	Morphine sulphate 10 mg/mL injection BP – Summary of Product Characteristics Wockhardt 2014
3574	Laboratorija	Ondansetron - Résumé des caractéristiques du produit Accord Healthcare France SAS 2013
3578	Laboratorija	Cisplatin - Summary of Product Characteristics Accord Healthcare 2011
3580	Laboratorija	Cytarabine Accord - Résumé des caractéristiques du produit Accord Healthcare France 2016
3634	Laboratorija	Oxaliplatine (Oxaliplatine Accord®) - Résumé des caractéristiques du produit Accord Healthcare 2011
3637	Laboratorija	Methotrexate (Methotrexate solution for injection®) - Summary of Product Characteristics Hameln Pharmaceuticals 2014
3645	Laboratorija	Doxorubicin - Summary of Product Characteristics Accord Healthcare 2014
3670	Žurnāls	Sewell G, Massimini M. Studies on the stability and compatibility of cytotoxic drug infusion with the Tevadaptor system. EJOP 2014 ; 8, 3: 26-30.
3873	Žurnāls	Tan X, Hu J. Incompatibility between irinotecan and fluorouracil injections Am J Health-Syst Pharm 2016 ; 73:755.
3948	Žurnāls	Bouchoud L, Fonzo-Christe C, Klingm?ller M, Bonnabry P . Compatibility of Intravenous Medications With Parenteral Nutrition - In Vitro Evaluation. JPEN 2012 ;30. 416?424.
4568	Žurnāls	Closset M,Onorati S, Colsoul M.L,Goderniaux N,Bihin B, Jamart J, Soumoy L, Hecq J.D, Odou P, Galanti L. Long-term physico-chemical stability of 5-fluorouracile at standardised rounded doses (SRD) in MyFuser® portable infusion pump. Journal of Chemotherapy 2021
4735	Žurnāls	Closset M, Onorati S, Colsoul M-L, Goderniaux N, Bihin B, Jamart J, Soumoy L, Hecq J-D, Odou P, Galanti L. Long-term physicochemical stability of 5-fluorouracil at selected standardised rounded doses in polyolefin bags. J Oncol Pharm Practice 2023 ;29,8:1878 - 1883
4759	plakāts	Ma NH, Charbonneau LF, Law S, Walker S. Stability of 5-fluorouracil at 4°C, 25°C, and 33°C stored in NiproSureFuser+ Ambulatory Balloon Infusers. Sunnybrook Healt Science Centre 2023

Mentions Légales